Actuate Therapeutics, Inc. (ACTU)
| Market Cap | 15.43M-90.6% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 23.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 75,978 |
| Open | 0.68 |
| Previous Close | 0.72 |
| Day's Range | 0.63 - 0.68 |
| 52-Week Range | 0.60 - 8.49 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 21.00(+3155.31%) |
| Earnings Date | n/a |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ACTU
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ACTU stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ACTU holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ACTU's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ACTU Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ACTU patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ACTU from public contracts
Source: USAspending.gov
ACTU Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ACTU’s recent data — informational, not investment advice